Side-by-side comparison of AI visibility scores, market position, and capabilities
Kaigo Health (YC F25) deploys AI voice agents for elderly outpatient follow-up, scaling post-visit check-ins 100x for Medicare providers who currently have near-zero between-visit care.
Kaigo Health is a healthcare AI startup founded in 2025 and headquartered in San Francisco, built to address one of the most persistent gaps in outpatient elderly care: the near-complete absence of structured follow-up between clinical visits. The company was accepted into Y Combinator's Fall 2025 batch, a validation of its founding team and market thesis at a very early stage. Kaigo targets the Medicare provider ecosystem, where outpatient follow-up is both a quality metric and a reimbursement driver under value-based care arrangements.\n\nKaigo's platform deploys AI voice agents that conduct follow-up calls with elderly patients between clinical encounters, checking on medication adherence, symptom changes, and overall wellbeing in a conversational, accessible format appropriate for older adults who may be less comfortable with app-based or text communication. The system scales these follow-up touchpoints by 100x compared to what a human care coordination team could accomplish at equivalent cost, dramatically expanding the reach of providers who want to improve patient engagement without proportional staffing increases.\n\nThe company is entering a market shaped by twin pressures: an aging US population driving record Medicare enrollment and a care workforce shortage that makes scaling high-touch care coordination through humans alone economically unsustainable. AI voice agents are increasingly recognized as a practical solution to this gap, particularly for the elderly population where voice interaction is natural and phone calls remain a trusted communication channel. Kaigo's early YC backing positions it alongside a cohort of companies building AI infrastructure for the future of value-based elder care.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.